News

Virginia Catalyst announces Grant Round 18 awarded teams

August 13, 2025  – The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.4 million in grants to three life and bioscience projects in the Commonwealth of Virginia through a highly-competitive Grant Round 18.

 

“The bioscience ecosystem in Virginia is vibrant, with university researchers, incubator, accelerators, mentors, and VA Bio working together to drive economic development in the Commonwealth.” said Mike Grisham, CEO of Virginia Catalyst. “The Catalyst is proud to provide an avenue of non-diluted funding for these teams to further develop their innovations into commercialization in life sciences.”

 

Through this 18th round of funding, Virginia Catalyst has awarded 72 grants totaling over $38 million, resulting in nearly $56 million in matching funds and over $660 million in follow-on funding and 450 jobs in life sciences.

 

Grant Round 18 Awarded Teams

    

Ceres Nanosciences (Manassas), University of Virginia, and Virginia Tech

  • Awarded: $800,000
  • “Nanotrap® SECURE (Sample Enrichment Concentration Universal RNA/DNA Extraction) Kit”

 

HTIC, Inc. (Charlottesville), University of Virginia, and Virginia Commonwealth University

  • Awarded: $800,000
  • “Developing a first-in-class humanized monoclonal antibody for immune modulation in human diseases”

  

RIVANNA Medical, Inc. (Charlottesville), University of Virginia, and Virginia Commonwealth University

  • Awarded: $800,000
  • “Transforming epidural placement with precision-guided technology to enhance safety and patient satisfaction”

 

 

Read more here.

 

Recent News

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like

03/17/2026

AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™

AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining

03/16/2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75